{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+Head&page=12",
    "query": {
      "condition": "Cancer of Head",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 3019,
    "total_pages": 302,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+Head&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+of+Head&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T14:01:46.800Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04682431",
      "title": "A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Gynecologic Cancer",
        "Breast Cancer",
        "Colorectal Cancer",
        "Gastric Adenocarcinoma",
        "Lung Adenocarcinoma",
        "Pancreatic Cancer",
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "PY159 Single agent dose level 1",
          "type": "DRUG"
        },
        {
          "name": "PY159 Single agent dose level 2",
          "type": "DRUG"
        },
        {
          "name": "PY159 Single agent dose level 3",
          "type": "DRUG"
        },
        {
          "name": "PY159 Single agent dose level 4",
          "type": "DRUG"
        },
        {
          "name": "PY159 Single agent dose level 5",
          "type": "DRUG"
        },
        {
          "name": "PY159 Single agent dose level 6",
          "type": "DRUG"
        },
        {
          "name": "PY159 Single agent dose level 7",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose level 1",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose level 2",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose level 3",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose level 4",
          "type": "DRUG"
        },
        {
          "name": "PY159 Single agent dose expansion cohort",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose expansion cohort 1",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose expansion cohort 2",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose expansion cohort 3",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose expansion cohort 4",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose expansion cohort 5",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose expansion cohort 6",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ikena Oncology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 127,
      "start_date": "2020-11-10",
      "completion_date": "2023-08-31",
      "has_results": false,
      "last_update_posted_date": "2024-03-22",
      "last_synced_at": "2026-11-18T14:01:46.800Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • San Francisco, California • Santa Monica, California + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04682431"
    },
    {
      "nct_id": "NCT02775812",
      "title": "Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7",
        "Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7",
        "Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2016-11-28",
      "completion_date": "2022-05-20",
      "has_results": false,
      "last_update_posted_date": "2022-06-10",
      "last_synced_at": "2026-11-18T14:01:46.800Z",
      "location_count": 69,
      "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 58 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02775812"
    },
    {
      "nct_id": "NCT01208051",
      "title": "Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Refractory Differentiated Thyroid Gland Carcinoma",
        "Refractory Thyroid Gland Follicular Carcinoma",
        "Refractory Thyroid Gland Hurthle Cell Carcinoma",
        "Refractory Thyroid Gland Papillary Carcinoma",
        "Unresectable Thyroid Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cediranib",
          "type": "DRUG"
        },
        {
          "name": "Cediranib Maleate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 127,
      "start_date": "2010-09-09",
      "completion_date": "2020-02-01",
      "has_results": true,
      "last_update_posted_date": "2021-07-15",
      "last_synced_at": "2026-11-18T14:01:46.800Z",
      "location_count": 30,
      "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 24 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "South Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01208051"
    },
    {
      "nct_id": "NCT01301495",
      "title": "Prospective Evaluation of a New Covered Metal Stent for Malignant Lesions of the Esophagus",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "HANAROSTENT TM covered Esophageal Stent",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2010-11",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2015-06-03",
      "last_synced_at": "2026-11-18T14:01:46.800Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01301495"
    },
    {
      "nct_id": "NCT00991094",
      "title": "Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Carcinoma",
        "Esophageal Carcinoma",
        "Genitourinary System Carcinoma",
        "Head and Neck Carcinoma",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Lung Carcinoma",
        "Malignant Central Nervous System Neoplasm",
        "Malignant Digestive System Neoplasm",
        "Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5000,
      "start_date": "2005-05-27",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-11-18T14:01:46.800Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00991094"
    },
    {
      "nct_id": "NCT01774851",
      "title": "A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HER-2 Gene Amplification",
        "Esophagus Cancer",
        "Gastroesophageal Junction Cancer",
        "Stomach Cancer"
      ],
      "interventions": [
        {
          "name": "MM-111",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merrimack Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2013-01",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2017-06-22",
      "last_synced_at": "2026-11-18T14:01:46.800Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Stanford, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01774851"
    },
    {
      "nct_id": "NCT06162377",
      "title": "Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A \"Window of Opportunity\" Pilot Study.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Methylnaltrexone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2024-01-10",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-11-18T14:01:46.800Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06162377"
    },
    {
      "nct_id": "NCT07023731",
      "title": "A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "KRAS G12D Mutation",
        "Advanced Solid Cancer"
      ],
      "interventions": [
        {
          "name": "ARV-806",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arvinas Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2025-05-29",
      "completion_date": "2026-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-11-17",
      "last_synced_at": "2026-11-18T14:01:46.800Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • New Haven, Connecticut • Tampa, Florida + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07023731"
    },
    {
      "nct_id": "NCT06997094",
      "title": "Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Papillomavirus-Negative Neck Squamous Cell Carcinoma",
        "Resectable Head and Neck Squamous Cell Carcinoma",
        "Resectable Human Papillomavirus-Independent Head and Neck Mucosal Squamous Cell Carcinoma",
        "HPV-Negative Squamous Cell Carcinoma",
        "Resectable Head and Neck Squamous-cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "External Beam Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Surgical Procedure",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2026-01-23",
      "completion_date": "2027-11-08",
      "has_results": false,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-11-18T14:01:46.800Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06997094"
    },
    {
      "nct_id": "NCT04570839",
      "title": "COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Neoplasms",
        "Ovarian Cancer",
        "Solid Tumor",
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "COM701 in combination with BMS-986207 and nivolumab.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Compugen Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2020-08-31",
      "completion_date": "2024-05-15",
      "has_results": false,
      "last_update_posted_date": "2024-07-18",
      "last_synced_at": "2026-11-18T14:01:46.800Z",
      "location_count": 9,
      "location_summary": "Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 6 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04570839"
    }
  ]
}